Company intelligence / Profile preview

Biosency

Cesson-Sévigné, Brittany, Francebiosency.com ↗

Ownership: Private
Development stage: Other

Overview

Clinical studies presented at ATS and French congresses show that the BVS3 technology integrated into the BORA Care® device can predict acute COPD exacerbations on average three days before hospitalization in approximately 86% of cases with only a ~9% false positive rate. The system enables early intervention to reduce hospitalizations and improve patient outcomes. MDR certification was obtained in June 2023; ANS interoperability/security certification was achieved by December 2023. Additional data collection continues for broader reimbursement.

Therapeutic areas: PulmonologyCardiovascular
Modalities: Device (connected medical device)Digital health platform (AI-based predictive analytics)Non-pharmacological therapy (remote monitoring solution)
Industry: Physiological Monitoring

Partnerships

Not explicitly listed; collaborations with French hospitals for clinical studies are noted.

Beyond the preview

Go deeper on Biosency.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biosency.

Explore the full profile